HGF/MET and the Immune System: Relevance for Cancer Immunotherapy.

Autor: Papaccio F; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania 'Luigi Vanvitelli', Via Pansini n.5, 80131 Naples, Italy. fede.papaccio@yahoo.it., Della Corte CM; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania 'Luigi Vanvitelli', Via Pansini n.5, 80131 Naples, Italy. carmy.dellacorte@gmail.com., Viscardi G; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania 'Luigi Vanvitelli', Via Pansini n.5, 80131 Naples, Italy. giuseppe.viscardi@hotmail.it., Di Liello R; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania 'Luigi Vanvitelli', Via Pansini n.5, 80131 Naples, Italy. diliello90@gmail.com., Esposito G; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania 'Luigi Vanvitelli', Via Pansini n.5, 80131 Naples, Italy. espositogiovanna87@gmail.com., Sparano F; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania 'Luigi Vanvitelli', Via Pansini n.5, 80131 Naples, Italy. franci.sparano@gmail.com., Ciardiello F; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania 'Luigi Vanvitelli', Via Pansini n.5, 80131 Naples, Italy. fortunato.ciardiello@unicampania.it., Morgillo F; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania 'Luigi Vanvitelli', Via Pansini n.5, 80131 Naples, Italy. florianamorgillo@yahoo.it.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2018 Nov 14; Vol. 19 (11). Date of Electronic Publication: 2018 Nov 14.
DOI: 10.3390/ijms19113595
Abstrakt: An overactivation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) axis promotes tumorigenesis and tumor progression in various cancer types. Research data recently evidenced that HGF/MET signaling is also involved also in the immune response, mainly modulating dendritic cells functions. In general, the pathway seems to play an immunosuppressive role, thus hypothesizing that it could constitute a mechanism of primary and acquired resistance to cancer immunotherapy. Recently, some approaches are being developed, including drug design and cell therapy to combine MET and programmed cell death receptor-1 (PD-1)/programmed cell death receptor-ligand 1 (PD-L1) inhibition. This approach could represent a new weapon in cancer therapy in the future.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje